About Robert Graifman
Form D filings for Thylacine Biotherapeutics in 2023 list Robert Graifman as director.
Robert Graifman first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Robert Graifman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Robert Graifman works with at each company, as listed on that company's latest Form D.
Thylacine Biotherapeutics Inc · Form D, Jan 19, 2023
DG
Daniel Graifman
Executive officer and director
AF
Andrew Fradkin
Secretary and General Counsel, director